Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices
Authors' conclusion
Clinicians still tend to choose CYC over RTX in induction therapy of SLE and AAV and mostly prefer the high-dose CYC treatment regimen suggested by the NIH.
Study context
- Population
- Pediatric rheumatologists and pediatric nephrologists administering CYC in childhood-onset rheumatic diseases
- Participants
- 87 participants
- Exposure
- Pediatric rheumatologists vs pediatric nephrologists
- Pediatric rheumatologists (PRs)n = 56
- Pediatric nephrologists (PNs)n = 31
- Outcome
- CYC practice
Methodological detailsweb-based questionnaire
- Web-based questionnaire
Main finding
As reported in the abstract
Monthly 500 mg/m² CYC for 6 months (NIH protocol)
- Most common indication for CYC: childhood-onset systemic lupus erythematosus (SLE)
- 95%
- Most common indication for CYC: ANCA-associated vasculitis (AAV)
- 69%
- Vaccine assessed: hepatitis B
- 82%
- Vaccine assessed: chickenpox
- 76%
- Vaccine assessed: mumps-measles-rubella
- 72%
- Clinicians performing gonad-sparing interventions before CYC
- 9
Observational data: associations, not effects.
Safety
Adverse effects associated with CYC (reported by clinicians)
- Cytopenia
- 86%
- Nausea
- 52%
- Liver toxicity
- 20%
- Hair loss
- 31%
- Hemorrhagic cystitis
- 37%
- Allergic reactions
- 16%
- Dyspnea
- 5%
- Infertility
- 2%
Original publication
Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices. Pediatr Rheumatol Online J. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →